Acrux(ASX) ACR

Acrux Limited specializes in the development and commercialization of generic and topically applied pharmaceutical products. The company operates globally, providing a range of testosterone therapies and estradiol sprays for various medical needs.

Products and Services

• Testosterone therapies including oral tablets, patches, and gels
• Estradiol sprays marketed as Evamist and Lenzetto for menopause management
• Innovative delivery systems for pharmaceutical applications

Growth Outlook

• Recent quarterly revenue reached AUD 2.9 million, indicating strong market demand
• Gross profit margin improved to 92.6% in the latest quarter
• Expansion into international markets is expected to drive future growth

Financial Highlights

• Trailing twelve months (TTM) revenue of AUD 8.4 million
• Net income for the latest quarter was a loss of AUD 769,000
• Current ratio stands at 1.37, indicating good short-term financial health

Acrux Limited has established itself as a key player in the biotechnology sector, focusing on innovative therapies for hormone-related conditions. The company's diverse product offerings cater to both men and women, addressing significant health issues such as testosterone deficiency and menopause symptoms. The recent financial performance shows promising trends, particularly with a notable increase in quarterly revenue and a high gross profit margin. Despite facing net losses, the company maintains a solid current ratio, suggesting it can meet its short-term obligations effectively. With ongoing efforts to expand into new markets and enhance its product portfolio, Acrux Limited presents an intriguing opportunity for investors interested in the biotechnology field. The company's commitment to innovation and market expansion may position it well for future growth.